Radioligand Therapy in 2026 and the Role of PSMA PET Imaging - Steven Finkelstein
Steven Finkelstein
Steven Finkelstein discusses radioligand therapy and PSMA PET imaging with drawing on his International Prostate Cancer Forum presentation and the published MD PET 1 multidisciplinary guidelines paper.
ABBV-969, a Dual-Targeted PSMA-STEAP1 ADC in Heavily Pretreated mCRPC - Tanya Dorff
Tanya Dorff
Tanya Dorff presents phase 1 data on ABBV-969, a dual-targeting antibody-drug conjugate binding PSMA and STEAP1 to deliver a topoisomerase payload in 49 heavily pretreated mCRPC patients.
